NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
This phase I trial studies the side effects of isatuximab and to see how well it works in treating patients with high risk immunoglobulin light chain amyloidosis (AL amyloidosis). Isatuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Sponsor
Emory University
Collaborators
Sanofi
National Cancer Institute (NCI)
Information provided by (Responsible Party)
Craig Hofmeister, Emory University
ClinicalTrials.gov Identifier: NCT04754945
Official Title: Slow-Go Strategy for High Risk AL Amyloidosis: Isatuximab for Upfront Therapy
First Posted : February 15, 2021
Click here to see details on ClinicalTrials.gov
Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Dexamethasone
Biological: Isatuximab
Locations
United States, Georgia
United States, California
United States, Michigan
United States, New York
United States, Texas